Detection of a deletion in the TMLHE gene, encoding trimethyllysine hydroxylase epsilon, in an individual with ASD led to the delineation of a novel inborn error of carnitine biosynthesis. 7 Subsequently, other TMLHE mutations identified in children with ASD raised the possibility of a relation between carnitine biosynthetic pathway defects and autism, 8, 9 leading to the hypothesis that brain carnitine deficiency may cause some cases of ASD. 10 Males born with the deficiency have a 3% chance of being diagnosed with ASD-2-fold higher than the general population's risk for males. A prospective double-blind, randomized clinical trial of levocarnitine to treat ASD found that levocarnitine therapy (50 mg/kg-body weight/day) for 3 months decreased ASD severity per scores on the Childhood Autism Rating Scale (CARS) 11 and the Autism Treatment Evaluation Checklist (ATEC). 12, 13 However, the authors felt that levocarnitine dosage may have been too low and that greater clinical improvements could be observed at higher doses.
We conducted an open-label, pilot trial among young males with ASD to examine dose compliance, attrition, and potential side effects of short-term, high-dose carnitine supplementation. Secondary outcomes focused on possible (1) behavioral improvements following carnitine supplementation and (2) biochemical-behavioral relationships between free carnitine levels in plasma and select behavioral indices.
Methods

Participants
Participants were 10 males (mean age = 59.8 months [5. 0 years], SD = 22.7 months [1.9 years], range = 31-92 months [2.7-7.7 years]) who were recruited from local samples of participants from the Simons Simplex Collection (SSC) 14 or the Autism Treatment Network. Six identified as Caucasian, 2 as Hispanic, 1 as biracial Caucasian/African American, and 1 as Asian Indian. One child had documented TMLHE deficiency and 3 had low carnitine levels (see Table 1 for details). Children were not asked to stop/withhold any therapies that they were pursuing at enrollment. None were taking medications that were contraindicated for high-dose carnitine supplementation.
Ethical Approval and Informed Consent
This study was approved by the Institutional Review Board at Baylor College of Medicine, and all participants provided written consent to cooperate with study procedures. ASD Symptomatology. Parent-reported information about children's ASD behaviors was gathered via the Autism Diagnostic Interview-Revised (ADI-R). 17 If a previous, research-reliable ADI-R was completed and available to the study team, those data were used. Current, clinicianobserved ASD behaviors were assessed via the Autism Diagnostic Observation Schedule (ADOS). 18 While the original ADOS was administered during the current study, subscale scores were calculated using the updated ADOS-2 19 algorithm. If a research-reliable ADOS was completed within 6 months of enrollment for the current study, then those data were used at baseline.
Instruments
Parent Report of Behavior Over Time. Parent ratings of current ASD behaviors were assessed using the Social Communication Questionnaire-Current version (SCQ), 20 the Pervasive Developmental Disorder Behavior Inventory (PDDBI), 21 and the Autism Impact Measure (AIM). 22 Problematic behaviors were assessed using the Aberrant Behavior Checklist (ABC). 
Procedures
Consenting families participated in an 8-week, openlabel trial of carnitine supplementation. Families were advised to report immediately any unusual behavior or adverse events and to keep a drug diary to record any doses missed during the trial.
Behavioral assessments and biochemical assays were collected at 3 time points: baseline (0 weeks), mid-treatment (4 weeks), and post treatment (8 weeks). Logistic and scheduling issues delayed posttreatment data collection for 4 cases beyond the planned 8-week window; however, all remained on carnitine supplementation until their final blood draw.
Medical Examination and Sample Collection.
A baseline physical examination was performed, and a medical history was taken to screen for medical conditions affected by high-dose carnitine supplements (eg, gastroenteritis). Blood and urine samples were taken at up to 3 different time points (baseline, mid-treatment, post treatment) to measure plasma carnitine and related metabolites, determine TMLHE deficiency, and screen for renal and liver function. Mid-treatment samples were not taken for 6 children who could not return to the study site. Safety laboratories were performed, and the final results were shared with the study team. The research blood samples were sent to the Beaudet Laboratory at Baylor College of Medicine.
Behavioral Assessments. At baseline, all children participated in cognitive testing with either the Mullen or the DAS-II; the ADOS and/or ADI-R were also administered to confirm ASD status. The ADOS was repeated at post treatment. All 10 participants had complete baseline data for the cognitive assessments and ADOS, and all but one had complete data for the ADI-R. Parents completed the SCQ, PDDBI, AIM, and ABC at baseline, mid-treatment, and post treatment to measure more subtle behavioral changes over time. Clinicians completed the CGIS at baseline and post treatment, with reports informed by their interactions with children during standardized assessments (ie, cognitive testing/ADOS at baseline, ADOS at post treatment).
Carnitine Supplementation. Participating children were administered oral suspension or tablets of levocarnitine in 3 divided doses, starting at 200 mg/kg/day and increasing to 400 mg/kg/day, with a maximum daily dose of 6 g. If a child experienced unpleasant side effects (ie, fishy body/breath odor, diarrhea), the maximum daily dose was dropped down to 200 mg/kg/day. Fisherman's soap and probiotics were recommended to further alleviate unpleasant side effects.
Statistical Analyses
Descriptive statistics were employed to characterize the sample demographically and phenotypically. Primary outcomes of interest were dose compliance, side effects, and attrition. Because this was an exploratory pilot trial, all subscale and total scores for the aforementioned measures were analyzed as secondary outcome variables. A random coefficient model was used to estimate the effect of time on carnitine supplementation on each outcome variable. The model included fixed effects for time and random coefficients for the intercept and time.
Because of convergence problems (ie, small sample size), the model for carnitine level in plasma only included a random slope, and the model for the AIM's Social-Emotional Reciprocity Frequency ratings only included a random intercept. Spearman's rank correlation statistic was used to estimate the correlation between carnitine levels and outcome measures by visit number (baseline = 1, mid-treatment = 2, post treatment = 3). Results from the CGIS were analyzed descriptively.
Results
The following side effects were reported: heavy odor (4 parents), diarrhea (4 parents), and sporadic vomiting (1 parent). The one child who experienced sporadic vomiting had a disruption in supplementation (ie, was off treatment for 7 days). Dose compliance was otherwise good, which was verified by increased levels of plasma carnitine from pre-to post-assessment. Three children could not tolerate up-titration because of increased side effects (odor, diarrhea). These children remained at the lower dosage, with one discontinuing supplementation by mid-treatment because odor remained too problematic for the family. Three parents indicated no observable side effects; one of these families was lost to follow-up after the mid-treatment assessment. Favorable anecdotes reported by families included the following: calmer behavior (2 parents), more energy (2 parents), increased prosocial behaviors (4 parents), greater awareness (2 parents), better eye contact (2 parents), and improved language skills (2 parents). A complete listing of dose titration, side effects, and anecdotal reports are presented in Table 1 .
Scores on the ABC Hyperactivity subscale, SCQ, PDDBI Social Pragmatic Problems domain, and AIM Social-Emotional Reciprocity Impact domain significantly decreased over time (indicating behavioral improvement) at the unadjusted .05 level. Similarly, PDDBI Social Approach Behaviors, PDDBI Expressive Social Communication Abilities Composite scores, and PDDBI Receptive/Expressive Social Communication Abilities Composite scores significantly increased over time (indicating behavioral improvement). However, there were no significant changes in any scores over time after adjusting for multiple comparisons using Holm's step-down Bonferroni correction (P ≥ .31; see Table 2 ).
Among all carnitine-outcome pairs for which there were at least 7 observations available, plasma carnitine levels were correlated with a number of PDDBI subscale scores, as well as the ABC Irritability subscale. Only the PDDBI Learning, Memory, and Receptive Language domain maintained statistical significance at the .05 level after adjusting for multiple comparisons (P = .04). All of these correlations surfaced only at visit 3 (see Table 3 ).
On the CGIS, 6 boys received improved Illness Severity ratings from baseline to post treatment. Most often, ratings shifted to the next, less severe category; however, for 1 child, ratings shifted from severely to moderately affected (see Figure 1) . Efficacy ratings per the CGIS reflected a combination of perceived improvement relative to side effects, the latter of which was largely based on parent anecdotal report and the family's adherence to study regimens. Five children were rated as showing improvement, and 2 children were rated as experiencing significant side effects (one of whom was rated as exhibiting decided improvement with partial remission of symptoms). Efficacy ratings for each child are provided in Table 1 , along with a description of what each score means.
Discussion
To our knowledge, this is the first study to examine the effects of high-dose carnitine supplementation on levels of free plasma carnitine and ASD symptoms/behaviors, as well as possible associations between the two, among a sample of young males with ASD. A prior trial of lowdose levocarnitine in children with ASD noted improvement in symptoms via the CARS, a modified global impression score (clinician rated), and the Speech and Cognitive subscales of the ATEC. 13 The current study differed in its design (open-label, nonrandomized, pilot trial), higher carnitine dosage (200 mg/kg/day increasing to 400 mg/kg/day), and use of multiple behavioral measures (ADOS, SCQ, PDDBI, AIM, ABC, CGIS). Additional advantages of the current work were that (1) participating children had been rigorously phenotyped at baseline and (b) use of the ADOS at post treatment afforded a standardized context for clinicians' ratings on the CGIS. In both studies, carnitine levels increased significantly with supplementation, as expected.
With regard to dose compliance and side effects/ adverse events, most children tolerated the initial low dose of carnitine (200 mg/kg/day) with minimal side effects, most often fishy odor and/or diarrhea. Only one child reported no side effects. Up-titration to 400 mg/kg/day sometimes increased the severity of side effects, and 3 participants returned to the initial dose. Attrition was likely affected by a combination of perceived behavioral benefit and severity of side effects, as the 2 children who discontinued at mid-treatment reportedly had no noticeable behavioral changes, and one of these experienced fishy odor to the point that the mother was concerned about school bullying. While fishy odor and diarrhea are generally considered "unpleasant," the cost-benefit ratio is likely balanced differently for each family. For example, another child maintained higher-dose supplementation with reported heavy odor, but the family completed the trial because they observed behavioral improvements. In terms of behavioral outcomes, it is difficult to compare results between our study and Geier et al's study 13 because different measures were used. However, general similarities are evident in terms of improvements in overall ASD symptoms (via the CARS and SCQ) and some language ratings ( children with these data were rated by clinicians as demonstrating some degree of improvement, with 2 rated as "much improved." None were rated as worse at post treatment. It is possible that children were more comfortable/compliant with post-treatment testing because of familiarity with the clinical setting/rater, or that examiner ratings were biased because of the openlabel design. However, behavioral outcomes were associated with increased carnitine levels at post treatment, which was also observed in Geier et al's 13 randomized, double-blinded, controlled design. It remains possible that more favorable outcomes would be observed among a younger sample of children where there may be greater developmental plasticity and responsiveness to carnitine treatment.
Limitations and Future Directions
While the current study focused on a well-characterized group of young males with ASD and gathered standardized data from multiple sources, there are important limitations to consider. The sample size was small and may have reduced power to detect more significant effects. Furthermore, the sample was heterogeneous for age, cognitive functioning, language abilities, and ASD severity. Thus, such a small sample precluded examination of multivariate models and interaction terms, which could elucidate factors that mediate/moderate potential effects of carnitine treatment on behavioral outcomes. This pilot trial was also open label, so parents and clinicians may have been biased in reporting behavioral improvements.
Next-step studies could address these limitations by implementing a double-blinded, randomized, placebocontrolled design and enrolling a larger, younger, and more homogeneous sample. However, the challenge is developing a placebo with comparable odor to the carnitine supplement (to retain blinding), which subsequently influences the degree to which families can be retained. Considering that several boys remained on a low/ reduced dose (200 mg/kg/day) of carnitine after the initial increase, lower dosing may reduce unfavorable side effects without sacrificing behavioral benefit. Future work may also seek to include measures that capture the positive qualitative caregiver observations in a standardized fashion.
